OverT Bio

OverT Bio operates at the cutting edge of cell and gene therapy, focusing on the development of next-generation cellular therapies for solid tumors. The company leverages innovative platforms such as OverTarget, which utilizes pooled functional screening and synthetic genomics to engineer immune cells. OverT Bio's team comprises computational and experimental biologists, immunologists, and genome engineers, all working together to create effective and safe treatments. The company is backed by top-tier TechBio investors and has published its scientific advancements in prestigious journals like Nature and The New England Journal of Medicine. OverT Bio serves the biotechnology and healthcare markets, targeting medical institutions and research organizations. Its business model revolves around the discovery and development of proprietary therapeutic solutions, generating revenue through partnerships, licensing agreements, and potentially direct sales of its therapies.

Keywords: cell therapy, gene therapy, solid tumors, immune cells, OverTarget, synthetic genomics, pooled screening, biotechnology, healthcare, TechBio investors.